Amitai N, Stafler P, Blau H, et al. - In the present study, the researchers sought to evaluate the long-term impact of palivizumab immunization and extreme prematurity (< 29 weeks) on respiratory symptoms and pulmonary function at adolescence. They investigated survivors of extreme prematurity (< 29 weeks) at 13-18 years of age (study group, SG). SG babies born immediately prior to palivizumab immunization (non-palivizumab group, NPG) were compared with those born immediately following implementation (PG) and the control group (CG). Sixty-four adolescents aged 15.76 ±1.52 years, mean ± SD, were involved. According to results, wheezing episodes, inhaler use and hospitalizations were uncommon for the SG. The adolescents of PG and NPG were not significantly different. Palivizumab had no discernable long-term protective effect. Nonetheless, adolescent survivors of extreme prematurity displayed good clinical and physiological results, with the exception of mildly elevated LCI in BPD individuals. Detected airway hyper reactivity at primary school age, reduced by adolescence.